Login / Signup

First-Row Transition 7-Oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine Metal Complexes: Antiparasitic Activity and Release Studies.

Álvaro Martín-MontesSandra Jimenez-FalcaoSantiago Gómez-RuizClotilde MarínJosé Manuel Méndez-Arriaga
Published in: Pharmaceuticals (Basel, Switzerland) (2023)
Leishmaniasis and Chagas disease are still considered neglected illnesses due to the lack of investment in research, despite the fact that almost one million new cases are reported every year. Four 7-oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine (HftpO) first-row transition complexes (Cu, Co, Ni, Zn) have been studied for the first time in vitro against five different species of Leishmania spp. ( L. infantum , L. braziliensis , L. donovani , L. peruviana and L. mexicana ) as well as Trypanosoma cruzi , showing higher efficacy than the reference commercial drugs. UV and luminescence properties were also evaluated. As a proof of concept, anchoring of a model high-effective-metal complex as an antiparasitic agent on silica nanoparticles was carried out for the first time, and drug-release behaviour was evaluated, assessing this new approach for drug vehiculation.
Keyphrases
  • drug release
  • trypanosoma cruzi
  • drug delivery
  • metal organic framework
  • quantum dots
  • aqueous solution
  • heavy metals
  • case control
  • drug induced
  • emergency department
  • adverse drug
  • risk assessment
  • infectious diseases